Drug Profile

Research programme: oxysterol-based antibiotics - MAX BioPharma/Metaba

Latest Information Update: 31 Mar 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator MAX BioPharma; METABA
Class Antibacterials; Small molecules; Sterols
Mechanism of Action Hedgehog protein modulators; Transforming growth factor beta modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

20 Feb 2025 MAX Biopharma and Metaba agree to co-develop oxysterol-based antibiotics for Bacterial infections
20 Feb 2025 Preclinical trials in Bacterial infections in USA (PO) prior to February 2025
04 Jun 2021 MAX Biopharma files for patent protection for 'Oxysterol compounds and uses thereof' in the US

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com